# EDGAR Filing Document

**Accession Number:** 0001256144
**File Stem:** 0001062993-23-003510
**Filing Date:** 2023-2
**Character Count:** 8535
**Document Hash:** e4ad0fde35f8645b3ead0e1745ca38d5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-23-003510.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001062993-23-003510

**CONFORMED SUBMISSION TYPE**: 4/A

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230104

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** RANDLE STUART A
- **CENTRAL INDEX KEY:** 0001256144

**FILING VALUES:**
- **FORM TYPE:** 4/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41403
- **FILM NUMBER:** 23632199

**MAIL ADDRESS:**
- **STREET 1:** 585 WEST 500 SOUTH
- **CITY:** BOUNTIFUL
- **STATE:** UT
- **ZIP:** 84010
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Comera Life Sciences Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001907685
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 874706968
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 12 GILL STREET
- **STREET 2:** SUITE 4650
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801
- **BUSINESS PHONE:** (617)871-2101

**MAIL ADDRESS:**
- **STREET 1:** 12 GILL STREET
- **STREET 2:** SUITE 4650
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801

## Ex-24

```

POWER OF ATTORNEY

     KNOW ALL BY THESE PRESENTS, that the undersigned hereby authorizes Jeffrey
S. Hackman, Michael G. Campbell, Jeffrey L. Quillen, Ryan M. Rourke Reed and
Stacie S. Aarestad, each acting singly, to execute and caused to be filed with
the United States Securities and Exchange Commission any and all documents or
filings, includingany amendments thereto, required to be so filed. The
undersigned hereby grantsto the attorney-in-fact full power and authority to do
and perform any and every act and thing whatsoever requisite, necessary or
proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do personally present, with full power of substitution, resubstitution or
revocation, hereby ratifying and confirming all that such attorney-in-fact, or
such attorney's-in-fact substitute or substitutes, shall lawfully do or cause
to be done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorney-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming any
of the undersigned's responsibilities to comply with all applicable laws,
including Sections 13 and 16 of the Securities Exchange Act of 1934.

     This Power of Attorney shall remain in full force and effect until revoked
by the undersigned in a signed writing delivered to the foregoing attorney-in-
fact.

     IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 11th day of August, 2022.

/s/ Stuart A. Randle
Name: Stuart A. Randle

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4/A

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>RANDLE STUART A<br><sub>(Last) (First) (Middle)</sub><br>C/O COMERA LIFE SCIENCES HOLDINGS, INC.<br>12 GILL STREET, SUITE 4650<br><sub>(Street)</sub><br>WOBURN, MA 01801<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-04 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Comera Life Sciences Holdings, Inc. [ CMRA ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-01-04 |  | P<sup>(1)</sup> |  | 33783 | A | 1.23<sup>(2)</sup> | 42469 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Warrant (Right to Buy) | 1.23<sup>(2)</sup> | 2023-01-04 |  | P<sup>(1)</sup> |  | 33783<sup>(3)</sup> |  | 2023-01-04 | 2028-01-04 | Common Stock | 67566 | $0.25 | 33783 | D |  |

---

### Footnotes:

(1) This Form 4/A is being filed to (i) correct a typographical error in the transaction code disclosed in Column 3 in Table I and Column 4 in Table II in the original Form 4, filed on January 6, 2023, from "A" to "P" and (ii) correct a typographical error in the power-of-attorney of the reporting person.

(2) The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 33,783 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules.

(3) The exercisability of the Warrants is subject to a 4.99% beneficial ownership limitation.

**Remarks:**
Exhibit 24 Power of Attorney filed herewith.

**Signature:** /s/ Ryan M. Rourke Reed, Attorney-in-Fact  
**Date:** 2023-02-14

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**